These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 10350032

  • 1. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder.
    Wilens TE, Biederman J, Spencer TJ, Frazier J, Prince J, Bostic J, Rater M, Soriano J, Hatch M, Sienna M, Millstein RB, Abrantes A.
    J Clin Psychopharmacol; 1999 Jun; 19(3):257-64. PubMed ID: 10350032
    [Abstract] [Full Text] [Related]

  • 2. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial.
    Bostic JQ, Biederman J, Spencer TJ, Wilens TE, Prince JB, Monuteaux MC, Sienna M, Polisner DA, Hatch M.
    J Child Adolesc Psychopharmacol; 2000 Jun; 10(3):205-16. PubMed ID: 11052410
    [Abstract] [Full Text] [Related]

  • 3. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures.
    Pelham WE, Swanson JM, Furman MB, Schwindt H.
    J Am Acad Child Adolesc Psychiatry; 1995 Nov; 34(11):1504-13. PubMed ID: 8543519
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
    Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A.
    J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
    [Abstract] [Full Text] [Related]

  • 5. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.
    Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, Schleifer D, Harding M, Linehan C, Geller D.
    Am J Psychiatry; 1996 Sep; 153(9):1147-53. PubMed ID: 8780417
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH, Greenbaum M, Arnold V, Yu M, Yan B, Jaffee M, Robertson B.
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [Abstract] [Full Text] [Related]

  • 8. An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder.
    Riggs PD, Thompson LL, Mikulich SK, Whitmore EA, Crowley TJ.
    J Am Acad Child Adolesc Psychiatry; 1996 Aug; 35(8):1018-24. PubMed ID: 8755798
    [Abstract] [Full Text] [Related]

  • 9. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
    Wigal TL, Newcorn JH, Handal N, Wigal SB, Mulligan I, Schmith V, Konofal E.
    CNS Drugs; 2018 Mar; 32(3):289-301. PubMed ID: 29557078
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L.
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [Abstract] [Full Text] [Related]

  • 11. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 12. Pemoline in adult attention deficit hyperactivity disorder: predictors of nonresponse.
    Heiligenstein E, Anders J.
    J Am Coll Health; 1997 Mar; 45(5):225-9. PubMed ID: 9069682
    [Abstract] [Full Text] [Related]

  • 13. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.
    Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H.
    J Clin Psychiatry; 2005 Feb; 66(2):253-9. PubMed ID: 15705013
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 15. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
    Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, Biederman J.
    J Clin Psychiatry; 2006 Jan; 67(1):137-47. PubMed ID: 16426100
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB, Nordbrock E, Adjei AL, Childress A, Kupper RJ, Greenhill L.
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [Abstract] [Full Text] [Related]

  • 17. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.
    Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA, Modafinil ADHD Study Group.
    J Clin Psychiatry; 2006 May; 67(5):727-35. PubMed ID: 16841622
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
    Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.
    J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
    [Abstract] [Full Text] [Related]

  • 19. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R.
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [Abstract] [Full Text] [Related]

  • 20. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
    Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, Babb D, Bai Y, Eberly LE, Nunes EV, Grabowski J.
    JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.